- Solid Biosciences Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Solid Biosciences Inc at Citi BioPharma Conference TranscriptSep 07, 2023
- Solid Biosciences Inc at Barclays Virtual Gene Editing & Therapy Summit TranscriptMay 24, 2023
- Solid Biosciences Inc at JMP Securities Life Sciences Conference TranscriptMay 15, 2023
- Solid Biosciences Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) TranscriptApr 24, 2023
- Solid Biosciences Inc at Needham Healthcare Conference (Virtual) TranscriptApr 20, 2023
- Solid Biosciences Inc at BMO Capital Markets BioPharma Spotlight Series: Genetic Medicine Delivery (Virtual) TranscriptMar 28, 2023
- Solid Biosciences Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Solid Biosciences Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Solid Biosciences Inc To Acquire Aavantibio Inc Call TranscriptSep 30, 2022
- Q1 2022 Solid Biosciences Inc Earnings Call TranscriptApr 27, 2022$9.65 (-16.98%)Earnings
- Solid Biosciences Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Solid Biosciences Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 28, 2021
- Solid Biosciences Inc at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- Q1 2021 Solid Biosciences Inc Earnings Call TranscriptMay 14, 2021$52.35 (-21.40%)Earnings
- Pfizer Inc, Avidity Biosciences, Sarepta Therapeutics, Solid Biosciences, and Ultragenyx Pharmaceutical at Guggenheim Partners Healthcare Talks: Genomic Medicines & Rare Disease (Virtual) TranscriptApr 01, 2021
- Solid Biosciences Inc. - Special Call TranscriptMar 15, 2021
- Solid Biosciences Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Solid Biosciences Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Q3 2020 Solid Biosciences Inc Earnings Call TranscriptNov 05, 2020$48.6Earnings
- Solid Biosciences Inc Annual Shareholders Meeting TranscriptJun 16, 2020
- Solid Biosciences Inc. - Special Call TranscriptDec 18, 2019
- Solid Biosciences Inc. - Special Call TranscriptNov 12, 2019
Pfizer Inc, Avidity Biosciences, Sarepta Therapeutics, Solid Biosciences, and Ultragenyx Pharmaceutical at Guggenheim Partners Healthcare Talks: Genomic Medicines & Rare Disease (Virtual) Transcript
All right, I think we're live. So good morning, and welcome to the Guggenheim Healthcare Talks, our signature Genomic Medicine & Rare Disease Conference Day. This is the second of our 9 panels, and this will primarily focus on Duchenne muscular dystrophy.
I am Debjit. I'm one of the senior analysts at Guggenheim, and joining us today is Michael Binks, the Vice President of Clinical Research from Pfizer; Sam Wadsworth, Clinical -- Chief Scientific Officer at Ultragenyx; Arthur Levin, Chief Scientific Officer at Avidity, Carl Morris, Chief Scientific Officer at Solid; and Ian Estepan, Chief Financial Officer at Sarepta.
Questions & Answers
So given we have a very packed panel, why don't I start first at Pfizer and more on sort of the challenge that we, on the outside are facing in trying to understand all the emerging data in the field. So even in younger patients, do
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)